Image Caption: Mechanisms of OVs mediating anti-tumor activity. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the ...

DUBLIN--(BUSINESS WIRE)--The "Oncolytic Virus Immunotherapy - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Oncolytic Virus Immunotherapy ...

SAN DIEGO, June 23, 2023 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of ...

Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that progressed on standard therapy. The next phase of a clinical trial will ...

Immunotherapy has revolutionized the way physicians treat cancer patients. Immunotherapy is a form of treatment that directs the patient’s immune system toward the tumor. This form of therapy aims to ...

STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and ...

Antitumor effect of PRaG therapy in a triple-negative breast cancer model. Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced ...

Phase I study of fulvestrant in combination with 177Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium.

Oncolytic viruses trigger immunogenic cell death in tumors, releasing signals that activate innate immune cells and promote tumor-specific T-cell responses. While some oncolytic viruses, including FDA ...